Takeshi Horii
9PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Sep 07, 2024
Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.Takeshi Horii, Chikako Masudo, Yui Takayanagi
|Sep 06, 2024
Factor affecting severe atherothrombotic cerebral infarction in patients with type 2 diabetes mellitus: Large-scale claim database analysis of Japan.Takeshi Horii, Yoichi Oikawa, Kasumi Kidowaki
|Jul 30, 2023
Real-world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score-matched model analysis in Japan.Takeshi Horii, Yoichi Oikawa, Akira Shimada
|Sep 20, 2022
Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan.Gen Mizutani, Takeshi Horii, Yoichi Oikawa
|Jul 13, 2021
Acute kidney injury in Japanese type 2 diabetes patients receiving sodium-glucose cotransporter 2 inhibitors: A nationwide cohort study.Takeshi Horii, Yoichi Oikawa, Narumi Kunisada
|Jan 15, 2021
On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.Takeshi Horii, Yoichi Oikawa, Koichiro Atsuda
Pageof 2
